» Articles » PMID: 24661785

Reliability of Causality Assessment for Drug, Herbal and Dietary Supplement Hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN)

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2014 Mar 26
PMID 24661785
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Because of the lack of objective tests to diagnose drug-induced liver injury (DILI), causality assessment is a matter of debate. Expert opinion is often used in research and industry, but its test-retest reliability is unknown. To determine the test-retest reliability of the expert opinion process used by the Drug-Induced Liver Injury Network (DILIN).

Methods: Three DILIN hepatologists adjudicate suspected hepatotoxicity cases to one of five categories representing levels of likelihood of DILI. Adjudication is based on retrospective assessment of gathered case data that include prospective follow-up information. One hundred randomly selected DILIN cases were re-assessed using the same processes for initial assessment but by three different reviewers in 92% of cases.

Results: The median time between assessments was 938 days (range 140-2352). Thirty-one cases involved >1 agent. Weighted kappa statistics for overall case and individual agent category agreement were 0.60 (95% CI: 0.50-0.71) and 0.60 (0.52-0.68) respectively. Overall case adjudications were within one category of each other 93% of the time, while 5% differed by two categories and 2% differed by three categories. Fourteen per cent crossed the 50% threshold of likelihood owing to competing diagnoses or atypical timing between drug exposure and injury.

Conclusions: The DILIN expert opinion causality assessment method has moderate interobserver reliability but very good agreement within one category. A small but important proportion of cases could not be reliably diagnosed as ≥50% likely to be DILI.

Citing Articles

Drug-Induced Liver Injury in Pregnancy: The U.S. Drug-Induced Liver Injury Network Experience.

Masood U, Venturini N, Nicoletti P, Dellinger A, Kleiner D, Bonkovsky H Obstet Gynecol. 2024; 143(6):819-823.

PMID: 38626448 PMC: 11098677. DOI: 10.1097/AOG.0000000000005585.


AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury: also useful for hepatobiliary surgeons.

Pinazo-Bandera J, Garcia-Cortes M, Andrade R Hepatobiliary Surg Nutr. 2023; 12(5):746-751.

PMID: 37886185 PMC: 10598316. DOI: 10.21037/hbsn-23-319.


Using an Automated Algorithm to Identify Potential Drug-Induced Liver Injury Cases in a Pharmacovigilance Database.

Pineda Salgado L, Gupta R, Jan M, Turkoglu O, Estilo A, George V Adv Ther. 2021; 38(9):4709-4721.

PMID: 34319549 PMC: 8408072. DOI: 10.1007/s12325-021-01856-x.


Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials.

Hey-Hadavi J, Seekins D, Palmer M, Coffey D, Caminis J, Abdullaev S Drug Saf. 2021; 44(6):619-634.

PMID: 33725335 PMC: 8184702. DOI: 10.1007/s40264-021-01051-5.


Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines.

Devarbhavi H, Aithal G, Treeprasertsuk S, Takikawa H, Mao Y, Shasthry S Hepatol Int. 2021; 15(2):258-282.

PMID: 33641080 DOI: 10.1007/s12072-021-10144-3.


References
1.
Garcia-Cortes M, Stephens C, Lucena M, Fernandez-Castaner A, Andrade R . Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol. 2011; 55(3):683-691. DOI: 10.1016/j.jhep.2011.02.007. View

2.
Maria V, Victorino R . Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997; 26(3):664-9. DOI: 10.1002/hep.510260319. View

3.
Lucena M, Andrade R, Fernandez M, Pachkoria K, Pelaez G, Duran J . Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006; 44(4):850-6. DOI: 10.1002/hep.21324. View

4.
Danan G, Benichou C . Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993; 46(11):1323-30. DOI: 10.1016/0895-4356(93)90101-6. View

5.
Fontana R, Watkins P, Bonkovsky H, Chalasani N, Davern T, Serrano J . Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009; 32(1):55-68. PMC: 3637941. DOI: 10.2165/00002018-200932010-00005. View